Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Gynecologic 4Sarcoma 1

Conditions

Ovarian Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Paclitaxel 7pembrolizumab 6olaparib 5Carboplatin 4Bevacizumab 4tisotumab vedotin 2niraparib 2mirvetuximab soravtansine 2durvalumab 2defactinib 2Topotecan 2Taxes 2Saline Solution 2Immunoglobulin G 2Disulfides 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1rucaparib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Bevacizumab × Gynecologic × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03737643 2025-01-29

DUO-O

AstraZeneca

Phase 3 Active not recruiting
1,407 enrolled 1 FDA
Gynecologic

Ovarian Neoplasms

NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,873 enrolled 17 charts 1 FDA
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡